Company Study of Jiangsu Hengrui Medicine 
  • Jun/2007
  • Hard Copy
  • USD $349
  • Pages:23
  • Single User License
    (PDF Unprintable)       
  • USD $349
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $698
  • Hard Copy + Single User License
  • USD $399

Jiangsu Hengrui Medicine Co., Ltd. mainly produces anti-tumor drugs, anti-infectious drugs, antibiotic drugs and drugs for operation, and the first kind generates most of the company's profit. In the consecutive seven years since it went public, the profit of main business has been increasing by 28.7% year-on-year, and the net profit has been enjoying a CAGR of 22%. In addition, the company successively purchased Chengdu Hengrui Pharmaceutical Co., Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd., and the latter became a new drug R&D center afterward.

The two R&D centers of the company are respectively located in Lianyungang and Shanghai, both having its own work division and pipelining production ability. Shanghai R&D center is mainly in charge of the prophase research of new drugs.

In the year of 2006, the company's sales revenue from anti-tumor drugs reached RMB 856 million, up 632% from a year earlier. New drugs were successively launched into the market and thus the era of oxaliplatin and docetaxel came up. The sales revenue of Narcotic analgesic drugs mainly including Levobupivacaine and Atracurium Besilate amounted to RMB 128 million, rising 472% year-on-year. And anti-infectious drugs mainly including clarithromycin realized sales revenue of RMB 247 million, a rise of 193% over 2005.

In the years of 2004-2006, the capital invested into R&D was RMB 80 million, 100 million and 120 million respectively, accounting for 7.01%, 8.48% and 8.43% of the annual revenue from main business separately. Five kinds of the company's new drugs are in clinic trial or in planned clinic trial currently.

It is forecasted that in the year of 2007, the sales revenue of Jiangsu Hengrui Medicine Co., Ltd. will reach RMB 1.71 billion from the main business, up by 20% year-on-year; the net profit will amount to RMB 301 million, up 45.4% from a year earlier. In 2008, the sales revenue from main business and the net profit will be RMB 2.03 billion and RMB 450 million respectively with a year-on-year growth of 18.7% and 49.5% separately.

Structure of Main Business of Hengrui Medicine Co., Ltd

Historical Statistics of the Hengrui's Operation (Unit: RMB Million)

1 Retrospect of the Hengrui's operation
1.1 Share rights alternation of listed companies
1.2 Statistics of profit from main business

2 Redefinition of new drugs
2.1 China's backward ability in developing new drugs
2.2 Leading R&D ability of the industry
2.3 Influence of the redefinition for new drugs

3 Development strategies
3.1 Patent-drug strategy
3.2 Internationalization strategy

4 Analysis on new products
4.1 Imrecoxib
4.2 Cartrofloxacin
4.3 Apatinib
4.4 Ambroxol

5 Profit forecast
5.1 Anti-tumor drugs
5.2 Drugs for operation
5.3 Anti-infectious drugs
5.4 Cardiovascular drugs
5.5 Forecast on the sales of other drugs
Alternation of equity structure during the process of private economy
Structure of Hengrui's revenue from main business
Product structure of Hengrui
Historical statistics of Hengrui's operation
Evolvement in developing new drugs
Forecasted sales from the company’s main anti-tumor drugs
Forecasted sales from drugs for operation
Forecasted sales from anti-infectious drugs
Forecasted sales from cardiovascular drugs
Forecasted sales from other drugs
Forecast on Hengrui's financial indicators
Forecast on Hengrui's profit

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号